Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study

Morris Kletzel, Howard M. Katzenstein, Paul R. Haut, Alice L. Yu, Elaine Morgan, Marleta Reynolds, Grant Geissler, Maryanne H. Marymount, Dachao Liu, John A. Kalapurakal, Richard M. Shore, Diana M.E. Bardo, Jennifer Schmoldt, Alfred W. Rademaker, Susan L. Cohn

Research output: Contribution to journalArticle

102 Scopus citations

Abstract

Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II Protocol. After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of high-dose cyclophosphamide and granulocyte colony-stimulating factor. Patients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the primary site. Results: Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Sufficient numbers of peripheral-blood stem cells were collected in all but one patient. Seventeen patients were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycles, and three patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. With a median follow-up of 38 months, the 3-year event-free survival and survival rates are 57% ± 11% and 79% ± 10%, respectively. Conclusion: The results of this pilot study demonstrate that it is feasible to intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and suggest that this treatment strategy may lead to improved survival for patients with high-risk neuroblastoma.

Original languageEnglish (US)
Pages (from-to)2284-2292
Number of pages9
JournalJournal of Clinical Oncology
Volume20
Issue number9
DOIs
StatePublished - May 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study'. Together they form a unique fingerprint.

  • Cite this

    Kletzel, M., Katzenstein, H. M., Haut, P. R., Yu, A. L., Morgan, E., Reynolds, M., Geissler, G., Marymount, M. H., Liu, D., Kalapurakal, J. A., Shore, R. M., Bardo, D. M. E., Schmoldt, J., Rademaker, A. W., & Cohn, S. L. (2002). Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study. Journal of Clinical Oncology, 20(9), 2284-2292. https://doi.org/10.1200/JCO.2002.06.060